c-Myc tag Peptide: Atomic Tool for Immunoassays & Cancer Biology

Executive Summary: The c-Myc tag Peptide (A6003, APExBIO) is a synthetic peptide matching amino acids 410–419 of the human c-Myc protein, designed for use as a displacement agent in immunoassays (product page). This reagent inhibits anti-c-Myc antibody binding with specificity, facilitating studies of transcription factor regulation and proto-oncogene function in cancer biology (his6-tag.com). The peptide exhibits high solubility in DMSO (≥60.17 mg/mL) and water with ultrasonic treatment (≥15.7 mg/mL), but is insoluble in ethanol. Recommended storage is desiccated at -20°C to maintain >99% purity and 1203.3 Da molecular weight (APExBIO). Mechanistically, c-Myc regulates transcription of genes involved in cell proliferation, differentiation, apoptosis, and stem cell self-renewal, with implications for cancer research (Wu et al., 2021).

Biological Rationale

The c-Myc protein is a nuclear transcription factor encoded by the MYC proto-oncogene. It orchestrates fundamental cellular processes, including cell cycle progression, ribosomal biogenesis, and apoptosis (Wu et al., 2021). Deregulated c-Myc expression is implicated in tumorigenesis across multiple cancer types. The c-Myc tag Peptide mimics a specific C-terminal epitope, enabling selective interaction with anti-c-Myc antibodies in immunoassays. This design facilitates detection, quantification, and competitive displacement of c-Myc-tagged fusion proteins, critical for mechanistic studies in cancer biology, transcriptional regulation, and cellular signaling pathways. Its atomic sequence and high purity ensure reproducibility and specificity in experimental workflows (his6-tag.com).

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide (sequence: EQKLISEEDL) competitively binds to anti-c-Myc monoclonal antibodies, displacing c-Myc-tagged fusion proteins from immunocomplexes. This enables elution or detection of tagged proteins in immunoassays including ELISA, western blot, co-immunoprecipitation, and affinity purification (3xflag.com). The peptide’s high sequence fidelity ensures selective antibody recognition, avoiding cross-reactivity. Mechanistically, c-Myc regulates gene transcription via interactions with E-box DNA sequences and modulation of downstream targets, such as cyclins (upregulation) and Bcl-2 (downregulation), impacting cell proliferation and apoptosis (Wu et al., 2021). Employing this peptide as a displacement reagent allows for precise interrogation of these regulatory networks in both normal and transformed cells.

Evidence & Benchmarks

• c-Myc tag Peptide specifically displaces c-Myc-tagged fusion proteins from anti-c-Myc antibody complexes in immunoprecipitation and western blot workflows (his6-tag.com).
• Demonstrates solubility ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (with ultrasonic treatment) at room temperature, supporting flexible experimental design (APExBIO).
• Purity typically exceeds 99% (analytical HPLC), minimizing background and off-target effects (APExBIO).
• c-Myc activation upregulates cyclin and ribosomal RNA/protein genes, while repressing p21 and Bcl-2, facilitating proliferation and apoptosis regulation in cancer cells (Wu et al., 2021).
• Recommended storage at -20°C (desiccated) preserves peptide integrity for at least 12 months; repeated freeze-thaw cycles are discouraged (APExBIO).

Applications, Limits & Misconceptions

The c-Myc tag Peptide enables:

• Displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibodies in immunoassays, enhancing detection specificity (3xflag.com).
• Functional studies of c-Myc-dependent transcriptional regulation and proto-oncogene amplification in cancer models.
• Reproducible control experiments in cell proliferation, apoptosis, and stem cell self-renewal research (prostate-apoptosis-response-protein-par-4-2-7-homo-sapiens.com).

This article extends the discussion in "c-Myc tag Peptide: Atomic Utility in Immunoassays & Cancer Biology" by providing new evidence on peptide solubility and workflow parameters, and clarifies mechanistic links to transcription factor regulation beyond prior summaries.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: The peptide is for research use only and is not validated for clinical applications (APExBIO).
• Insolubility in ethanol: Attempting to dissolve the peptide in ethanol leads to precipitation and loss of activity.
• Long-term solution storage: Solutions are unstable; only freshly prepared aliquots should be used for optimal results.
• Cross-reactivity: The peptide is highly specific; non-specific antibody interactions are rare but can occur if antibodies are not validated.
• Not a direct cell cycle modulator: The peptide does not alter cell cycle parameters unless used in conjunction with tagged constructs or as part of a displacement assay.

Workflow Integration & Parameters

For immunoassays, add c-Myc tag Peptide at concentrations ranging from 0.1 to 1 mM to the antibody-protein complex. Confirm displacement via SDS-PAGE or ELISA analysis. Solubilize peptide in DMSO (≥60.17 mg/mL) or in water with ultrasonication (≥15.7 mg/mL), avoiding ethanol. Store lyophilized peptide at -20°C, desiccated. Use blue ice for shipping to maintain stability. APExBIO recommends avoiding repeated freeze-thaw cycles to preserve >99% purity and biological activity. For detailed troubleshooting and advanced application guidance, see this resource, which this article updates with new solubility and workflow data.

Conclusion & Outlook

The c-Myc tag Peptide from APExBIO serves as a robust, specific tool for research on transcription factor regulation, cell proliferation, apoptosis, and proto-oncogene-driven cancer biology. Its atomic purity and precise displacement function facilitate reproducible immunoassay workflows. Continued adoption will accelerate discoveries in gene amplification, autophagy regulation, and targeted therapeutic development. For the latest benchmarks and mechanistic updates, consult both the product page and relevant peer-reviewed literature (Wu et al., 2021).